News

Aggressive hybrid mutual funds see 13% YoY AUM jump, touch Rs 2.5 lakh crore in October

Nomura has initiated coverage on Anthem Biosciences with a Buy rating and a 740 target, citing attractive valuations, strong CRDMO positioning, diversified capabilities, and robust revenue and earnings growth projections despite recent stock correction.